A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19

Baricitinib is an oral, selective inhibitor of Janus kinase (JAK)1/JAK2 that transiently and reversibly inhibits many proinflammatory cytokines. This mechanism is a key mediator in a number of chronic inflammatory diseases; accordingly, baricitinib has been studied and approved for the treatment of...

Descripción completa

Detalles Bibliográficos
Autores principales: Bieber, Thomas, Feist, Eugen, Irvine, Alan D., Harigai, Masayoshi, Haladyj, Ewa, Ball, Susan, Deberdt, Walter, Issa, Maher, Grond, Susanne, Taylor, Peter C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9443639/
https://www.ncbi.nlm.nih.gov/pubmed/36063279
http://dx.doi.org/10.1007/s12325-022-02281-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9443639/
https://www.ncbi.nlm.nih.gov/pubmed/36063279
http://dx.doi.org/10.1007/s12325-022-02281-4

Ejemplares similares